source
- AbbVie's Skyrizi sales growth raises investor worries about J&J competitionDuring AbbVie's first-quarter earnings call, analysts focused on the company's immunology franchise and asked how it would defend Skyrizi against emerging competition from Johnson & Johnson. The c…
- FDA schedules first oncology advisory panel in nine months, will review AstraZeneca candidatesThe FDA announced it will hold an oncology advisory committee meeting roughly nine months from now. The meeting will focus on evaluating a pair of investigational drugs from AstraZeneca, though de…